The BrainGate2 Neural Interface System aims to provide a novel solution for individuals with severe speech impairments, particularly those suffering from conditions like ALS. The potential market includes a significant population of patients with anarthria and dysarthria, representing a niche yet impactful segment within the assistive technology landscape. The competitive landscape includes other neuroprosthetic devices, but the unique focus on speech restoration may offer a distinct advantage. Successful outcomes could lead to partnerships with rehabilitation centers and technology firms, enhancing market penetration. Diligence implications include assessing regulatory pathways and reimbursement strategies, given the unapproved status of the device.